NCT07481058 2026-03-18
A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
Clinical Trials
20 trialsNCT06657144 2026-03-02
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Recruiting
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT07272291 2025-12-09
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT05427396 2025-12-03
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07177794 2025-09-17
EC-CRT-008
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT06588335 2024-09-19
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Henan Provincial People's Hospital
Phase 2 Not yet recruiting
NCT06187597 2024-03-12
EC-CRT-007
Sun Yat-sen University
Phase 2 Recruiting
NCT04844385 2024-02-09
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT05791136 2023-03-30
TREE
The Central Hospital of Lishui City
Phase 2 Not yet recruiting
NCT05163483 2023-03-06
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT04005170 2022-08-23
Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04177797 2022-02-09
Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT02915432 2021-12-13
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT04880811 2021-07-13
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
Peking University
Phase 2 Unknown
NCT04644250 2020-11-25
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT04229849 2020-01-18
Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 2 Unknown
NCT04006041 2019-12-26
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Unknown